Lysosomal Storage Diseases

Overview

Lysosomal Storage Diseases (LSDs) are inherited disorders in which a lysosome—the cell’s recycling compartment—cannot properly break down or transport particular molecules. The resulting buildup can damage many organs, including the brain, liver, kidneys, heart, bones, muscles, eyes, and immune system. Severity varies widely: some forms begin in infancy and cause rapidly progressive, life-threatening neurologic disease, while others emerge in adolescence or adulthood and progress more slowly. Collectively, lysosomal diseases are estimated to affect roughly 1 in 5,000 newborns. Lysosomal Disease Network overview

Current care is disease-specific and usually slows or manages disease rather than permanently correcting its cause. Available options include lifelong enzyme-replacement therapy (ERT), substrate-reduction therapy, pharmacologic chaperones that stabilize certain mutant enzymes, hematopoietic stem-cell transplantation for selected diseases and patients, and supportive multidisciplinary care. ERT can substantially improve some body-wide manifestations but generally has limited access to the brain because of the blood–brain barrier. Enzyme replacement therapy review Intrauterine ERT review

Scope of Recent Research (2020–present)

Research activity from 2020 through August 8, 2026 has been unusually broad, spanning systemic and brain-directed gene transfer, autologous stem-cell gene therapy, gene editing, RNA medicines, improved enzymes, and biomarker platforms. The dominant questions are whether treatment can deliver enough functional protein to the brain and other hard-to-reach tissues, begin early enough to prevent irreversible injury, and remain safe and durable for decades. Several programs now show sustained biochemical correction in people, but the evidence still supports a cautious conclusion: the field is moving toward potentially transformative therapies for individual LSDs, not a near-term universal cure for the entire group. Biomarkers for LSD gene-therapy trials MPS VI gene-therapy follow-up GM2 gene-therapy trial

Major Breakthroughs and Emerging Therapies

Adeno-associated virus (AAV) gene transfer has produced some of the strongest recent clinical signals. In mucopolysaccharidosis type VI (MPS VI), a phase 1/2 liver-directed AAV8 therapy supplied the ARSB enzyme gene in a single intravenous infusion. Four children followed for a median of 45 months maintained serum enzyme activity at 38% to 67% of healthy-reference values, and no late-emerging safety events were reported; however, urinary disease substrate rose modestly and one participant restarted ERT. This is important proof that the liver can act as a long-term factory for a missing lysosomal enzyme, but it does not yet establish full clinical correction. MPS VI gene-therapy follow-up

For neurologic LSDs, investigators are trying to place the therapeutic gene directly in the central nervous system. A 2025 phase 1/2 GM2 gangliosidosis study used two AAVrh8 vectors carrying HEXA and HEXB, delivered by bilateral thalamic infusion plus cerebrospinal-fluid routes. The study showed dose-related increases in enzyme activity and feasibility of the surgical approach; at the highest dose, cerebrospinal-fluid HexA activity reached about 13% of average normal activity. Some clinical measures were stable or improved over the short follow-up, but enzyme activity later declined and the investigators emphasized that broader brain distribution and durable clinical benefit remain unresolved. GM2 gene-therapy trial

Autologous hematopoietic stem-cell gene therapy—collecting a patient’s blood-forming stem cells, adding a functional gene with a lentiviral vector outside the body, and reinfusing the cells after conditioning chemotherapy—has also advanced. In the Canadian FACTs phase 1 cohort for Fabry disease, five men received gene-modified CD34-positive cells designed to produce alpha-galactosidase A. At five years, all had sustained production of the enzyme; plasma lyso-Gb3, a disease biomarker, decreased in four of five participants, and kidney symptoms were reported as stable. Five-year Fabry gene-therapy results In cystinosis, a 2026 phase 1/2 report found persistent engraftment and decreased white-cell cystine in five of six treated adults after CTNS-RD-04, supporting further development while underscoring the risks and burden of myeloablative conditioning. Cystinosis stem-cell gene therapy

Gene editing and RNA approaches remain earlier-stage but could widen the range of treatable LSDs. In a 2020 Tay–Sachs/Sandhoff mouse study, AAV-delivered CRISPR editing inserted a synthetic HEXM gene into the liver albumin locus, allowing edited liver cells to secrete an enzyme designed to compensate for either HEXA or HEXB deficiency. CRISPR editing for Tay–Sachs and Sandhoff disease In a 2025 Gaucher mouse study, lipid nanoparticles carrying messenger RNA for glucocerebrosidase produced enzyme in relevant immune-cell populations and reduced serum lyso-GL1, a key Gaucher biomarker. These approaches are promising, but neither has yet demonstrated a human cure. Lipid-nanoparticle mRNA for Gaucher disease

Small molecules remain valuable as complementary rather than curative strategies. For example, lucerastat inhibits synthesis of some glycosphingolipid substrates in Fabry disease, but its randomized phase 3 trial did not improve the primary neuropathic-pain endpoint despite reducing plasma Gb3. This result illustrates a central lesson for LSD research: lowering a biochemical marker is encouraging, but it does not automatically translate into meaningful clinical benefit. Lucerastat phase 3 Fabry study

Clinical Trials and Experimental Approaches

The MPS VI AAV8.TBG.hARSB study, sponsored by Fondazione Telethon, is a phase 1/2 open-label trial of liver-directed gene transfer. Its long-term report provides evidence of sustained enzyme expression after one infusion but also shows why trials must measure substrate levels and organ function, not enzyme activity alone. MPS VI ClinicalTrials.gov record MPS VI gene-therapy follow-up The GM2 program, conducted through UMass Chan Medical School with clinical efficacy assessments at Massachusetts General Hospital, completed a phase 1/2 dose-escalation study; its investigators reported relative safety and biological activity but called for further work to determine whether the delivery route can achieve sufficient central-nervous-system coverage and functional benefit. GM2 gene-therapy trial

CTNS-RD-04 for cystinosis was a completed six-person phase 1/2 study led by Stephanie Cherqui at the University of California, San Diego. Participants received their own CD34-positive stem cells after lentiviral addition of CTNS; the trial reported durable polyclonal blood-cell reconstitution, no evidence of monoclonal expansion, and reduced white-cell cystine in all but the lowest-vector-copy-number participant. A separate long-term follow-up study is designed to monitor safety, engraftment, and disease outcomes for up to 15 years. CTNS-RD-04 phase 1/2 trial record Cystinosis stem-cell gene therapy CTNS-RD-04 long-term follow-up record

The completed Canadian FACTs trial provides a useful early benchmark for lentiviral stem-cell therapy in Fabry disease. Its phase 1 cohort was small and uncontrolled, so it cannot prove superiority over existing therapy, but five-year enzyme production, biomarker improvement in most participants, and stabilization of kidney symptoms justify larger controlled studies. Five-year Fabry gene-therapy results

Methodologies and Scientific Approaches

Researchers combine disease-specific animal models with patient-derived cells to test whether treatments reach the cell types that actually drive damage. For example, investigators have generated induced pluripotent stem-cell-derived myelinating organoids and microglia from people with Krabbe disease, revealing early myelination defects and providing a human model for therapy testing. Krabbe iPSC organoid model Other teams are developing methods such as tagless LysoIP to isolate intact lysosomes from patient blood cells and perform molecular profiling directly on affected tissue. Tagless LysoIP platform

Delivery platforms are matched to the disease target: intravenous AAV can use the liver to release enzyme into circulation; direct brain or cerebrospinal-fluid AAV delivery seeks to reach neurons; lentiviral modification of stem cells aims for life-long production by descendant blood cells; and lipid nanoparticles may enable repeatable mRNA dosing. Trials increasingly pair these platforms with enzyme activity, stored-substrate measurements, imaging, neurodevelopmental testing, and organ-function outcomes because slowly progressive diseases require biomarkers that can predict, rather than merely accompany, clinical benefit. MPS VI gene-therapy follow-up GM2 gene-therapy trial Biomarkers for LSD gene-therapy trials

Leading Institutions and Funding

Key academic and clinical centers include the Telethon Institute of Genetics and Medicine and collaborating European centers in MPS VI gene therapy; UMass Chan Medical School, Massachusetts General Hospital, Washington University in St. Louis, and the National Human Genome Research Institute in the GM2 program; McMaster University and Juravinski Hospital in the Canadian Fabry study; and the University of California, San Diego in cystinosis stem-cell gene therapy. MPS VI gene-therapy follow-up GM2 gene-therapy trial Five-year Fabry gene-therapy results CTNS-RD-04 phase 1/2 trial record

The U.S. Lysosomal Disease Network has provided national infrastructure for longitudinal studies, newborn-screening research, trial readiness, and investigator training through NIH support from the National Center for Advancing Translational Sciences, the National Institute of Neurological Disorders and Stroke, and the National Institute of Diabetes and Digestive and Kidney Diseases. NIH awarded approximately $26 million in fiscal year 2025 to begin the fifth funding cycle for the wider Rare Diseases Clinical Research Network; that amount supports the network overall rather than LSD research alone. Lysosomal Disease Network funding and program

Strengths, Limitations, and Challenges

The strongest feature of current LSD research is that therapies now target root molecular defects rather than only downstream symptoms. Single-dose AAV treatment can produce multi-year enzyme expression, and stem-cell gene therapy can establish durable gene-marked blood-cell populations. MPS VI gene-therapy follow-up Cystinosis stem-cell gene therapy However, the central scientific obstacle remains delivering adequate treatment to the brain before neurodegeneration becomes irreversible. Systemic ERT usually does not adequately access the central nervous system, while direct brain delivery is invasive and may not distribute evenly through the entire brain. Intrauterine ERT review GM2 gene-therapy trial

Safety and interpretation are equally important constraints. AAV can provoke anti-capsid immune responses even with immunosuppression, and current neurological studies are small, heterogeneous, and often lack untreated controls. GM2 gene-therapy trial Stem-cell approaches require chemotherapy-based conditioning and long-term surveillance for insertion-related risks, while biomarker reductions may not predict preserved cognition, mobility, kidney function, or survival. Cystinosis stem-cell gene therapy Biomarkers for LSD gene-therapy trials

Outlook and Future Directions

As of August 8, 2026, a cure for LSDs as a group is not imminent, but several individual disorders have moved from theoretical gene correction to durable human biological signals. The milestones to watch are longer follow-up showing stable enzyme production without unacceptable toxicity, controlled evidence that biomarker changes preserve real-world neurologic and organ function, delivery systems that reliably reach the whole brain, and treatment before symptoms through newborn screening or potentially prenatal intervention. Success will likely arrive disease by disease, with the first genuinely curative outcomes most plausible where early diagnosis, a measurable biomarker, and effective whole-body or central-nervous-system delivery can be combined. Biomarkers for LSD gene-therapy trials Intrauterine ERT review GM2 gene-therapy trial

References

• Lysosomal Disease Network overview — Rare Diseases Clinical Research Network, 2026.
• Enzyme replacement therapy review — Puhl and Ekins, 2022.
• Intrauterine ERT review — Matern et al., 2023.
• Biomarkers for LSD gene-therapy trials — Rossi et al., 2024.
• MPS VI gene-therapy follow-up — Rossi et al., 2024.
• MPS VI ClinicalTrials.gov record — U.S. National Library of Medicine, 2026.
• GM2 gene-therapy trial — Eichler et al., 2025.
• Five-year Fabry gene-therapy results — Khan et al., 2025.
• Cystinosis stem-cell gene therapy — Barshop et al., 2026.
• CTNS-RD-04 phase 1/2 trial record — U.S. National Library of Medicine, 2026.
• CTNS-RD-04 long-term follow-up record — U.S. National Library of Medicine, 2026.
• CRISPR editing for Tay–Sachs and Sandhoff disease — Ou et al., 2020.
• Lipid-nanoparticle mRNA for Gaucher disease — Liu et al., 2025.
• Lucerastat phase 3 Fabry study — Germain et al., 2025.
• Krabbe iPSC organoid model — Evans et al., 2024.
• Tagless LysoIP platform — Saarela et al., 2024.
• Lysosomal Disease Network funding and program — Lysosomal Disease Network, 2026.